Beigene Co. Ltd. has divulged antibody-drug conjugates (ADC) comprising HER3 (erbB3) targeting antibody linked to an effector molecule through a linker reported to be useful for the treatment of cancer, metabolic diseases, neurodegeneration and inflammation.

Hitgen Ltd. has identified menin (MEN1)/MLL interaction inhibitors reported to be useful for the treatment of cancer.

Eil Therapeutics Inc. has synthesized apoptosis regulator Bcl-2 inhibitors reported to be useful for the treatment of cancer.

Hangzhou Adamerck Pharmlabs Inc. has disclosed uracil derivatives reported to be useful for the treatment of cardiovascular and cerebrovascular disorders.

Engrail Therapeutics Inc. has described deuterated compounds reported to be useful for the treatment of encephalopathy.

Astellas Pharma Inc. has divulged substituted quinolone derivates acting as acetylcholine receptor cluster inducers reported to be useful for the treatment of neuromuscular disorders.

Alchemedicine Inc. has identified angiotensin AT1 receptor (AGTR1) antagonists reported to be useful for the treatment of hypertension.

Shanghai Haiyan Pharmaceutical Technology Co. Ltd. and Yangtze River Pharmaceutical Group have synthesized macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer.

Researchers at Association Française Contre Les Myopathies, Consiglio Nazionale delle Ricerche, and Università degli Studi di Roma La Sapienza have disclosed peptidomimetics derived from leucyl-tRNA synthetase.

Researchers at Shanghai Jingxin Biomedical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have described fused bicyclic heteroaryl amide compounds acting as α-synuclein (SNCA) aggregation inhibitors reported to be useful for the treatment of frontotemporal, Lewy body and Parkinson's dementia, multiple system atrophy, and more.